Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German study-group multiple myeloma (DSMM)

Bone Marrow Transplantation

Volumn 31, Issue 11, 2003, Pages 973-979

  Kröger, Nicolaus ^a   Einsele, Hermann ^b   Wolff, Daniel ^c   Casper, Jochen ^c   Freund, Mathias ^c   Derigs, Günter ^d   Wandt, Hannes ^e   Schafer Eckart K ^e   Wittkowsky, Georg ^f   Schmitz, Norbert ^f   Krüger, William ^a   Zabelina, Tatjana ^a   Renges, Helmut ^a   Ayuk, Francis ^a   Krüll, Andreas ^a   Zander, Axel ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^e KLINIKUM NÜRNBERG   (Germany)

^f University Hospital ^*

Author keywords

Anti thymocyte globulin; Multiple myeloma; Stem cell transplantation; Total marrow irradiation

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BUSULFAN; CD20 ANTIGEN; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE ANTIBODY; FLUCONAZOLE; GANCICLOVIR; GLOBULIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELPHALAN; MYELOABLATIVE AGENT; OFLOXACIN; PENTAMIDINE; PHENYTOIN; STEROID; THALIDOMIDE; THYMOCYTE ANTIBODY;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOGRAFT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DEATH; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; FEMALE; FOLLOW UP; GERMANY; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; LIVER TOXICITY; LYMPHOCYTE DEPLETION; LYMPHOMA; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE MYELOMA; MULTIPLE ORGAN FAILURE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEIZURE; SEPSIS; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; WHOLE BODY RADIATION;

ACUTE DISEASE; ADULT; ANTILYMPHOCYTE SERUM; BUSULFAN; CHRONIC DISEASE; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; SURVIVAL RATE; T-LYMPHOCYTES; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 0038009391     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704049     Document Type: Article

References (28)

1. Gahrton G, Tura S, Ljungman P et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995; 13: 1312-1322.
2. Verdonck L, Lokhorst HM, Dekker AW et al. Graft versus myeloma effect in two cases. Lancet 1996; 347: 800-801.
3. Tricot G, Vesole DH, Jagannath S et al. Graft versus myeloma effect: proof of a principle. Blood 1996; 87: 1196-1198.
4. Lokhorst HM, Schattenberg A, Cornelissen JJ et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997; 90: 4206-4211.
5. Björkstrand B, Ljungman P, Svensson H et al. Allogeneic bone marrow transplantation vs autologous stem cell transplantation in multiple myeloma: a retrospective case matched study from the European Group for Blood and Marrow Transplantation. Blood 1996; 88: 4711-4718.
6. Reece DE, Shepherd JD, Klingemann HG et al. Treatment of myeloma using intensive therapy and allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15: 117-123.
7. Majolino I, Corradini P, Scime R et al. Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant 1998; 22: 449-455.
8. Anderson KC, Andersen J, Soiffer R et al. Monoclonal antibody purged bone marrow transplantation therapy for multiple myeloma. Blood 1993; 82: 2568-2576.
9. Schlossman RL, Webb I, Alyea EP et al. Similar disease free survival after allografting and autografting for multiple myeloma. Blood 1997; 10 (Suppl. 1): 994.
10. Gahrton G, Svenson H, Cavo M et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001; 13: 209-216.
11. Badros A, Barlogie B, Morris C et al. High response rate in refractory and poor risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001; 97: 2574-2579.
12. Garban F, Attal M, Rossi JF et al. Immunotherapy by nonmyeloablative allogeneic stem cell transplantation in multiple myeloma: results of a pilot study as salvage therapy after autologous transplantation. Leukemia 2001; 15: 642-646.
13. Kröger N, Schwerdtfeger R, Kiehl M et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002; 100: 755-760.
14. Finke J, Bertz H, Schmoor C et al. Allogeneic transplantation from unrelated donors using in vivo T-cell depletion. Br J Haematol 2000; 11: 303-313.
15. Kröger N, Zabelina T, Krüger W et al. Anti-thymocyteglobulin as part of the preparative regimen prevents acute and chronic graft versus host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors. Ann Hematol 2001; 80: 209-215.
16. Bearman SI, Appelbaum FR, Buckner CD. Regimen related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
17. McDonald GB, Hinds MS, Fisher LD. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267.
18. Przepiorka KM, Weisdorf D, Martin P. 1994 Consensus conference on acute GvHD-grading. Bone Marrow Transplantation 1995; 15: 825-828.
19. Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. Br J Haematol 1998; 120: 1115-1123.
20. Kröger N, Krüger W, Renges H et al. Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma. Br J Haematol 2001; 112: 421-423.
21. Marit G, Facon T, Jouet JP et al. Allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle. Blood 1997; 10 (Suppl. 1): 996.
22. Bensinger W, Buckner CD, Anasetti C et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996; 88: 2787-2793.
23. Huff CA, Noga SJ, Jones RJ. Allogeneic bone marrow transplantation: role of T cell depletion and graft versus host disease. Blood 2000; 96 (Suppl. 1): 862.
24. Kolb HJ, Holler E, Knabe H et al. Conditioning treatment with antithymocyte globulin (ATG) modifies graft-vs-host disease in recipients of marrow from unrelated donors. Blood 1995; 86 (Suppl. 1): 952a.
25. Zander AR, Zabelina T, Kröger N et al. Use of a five-agent GvHD prevention regimen in recipients of unrelated donor marrow. Bone Marrow Transplantation 1999; 23: 889-893.
26. Eiermann TH, Lambrecht P, Zander AR. Monitoring antithymocyte globulin (ATG) in bone marrow recipients. Bone Marrow Transplantation 1999; 23: 779-781.
27. Einsele H, Bamberg M, Zander AR et al. Total marrow irradiation (TMI), busulfan and cyclophosphamide followed by PBSCT in patients with multiple myeloma. Blood 1998; 92 (Suppl. 1): 516.
28. Kröger N, Sayer HG, Schwerdtfeger R et al. Unrelated stem cell transplantation in multiple myeloma after a reduced intensity conditioning with pretransplant anti-thymocyte globulin is highly effective with low transplantation related mortality. Blood 2002; 100: 3919-3924.